Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues.

Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues.

Neuroendocrine tumours (NETs) constitute a heterogeneous group of tumours that frequently express cell membrane-specific peptide receptors, such as somatostatin receptors (SSTRs), and of which gastroenteropancreatic (GEP), carcinoid and pancreatic islet cell tumours exhibit the highest expression of...

Full description

Bibliographic Details
Main Authors:	Kaltsas, G, Papadogias, D, Makras, P, Grossman, AB
Format:	Journal article
Language:	English
Published:	2005

Similar Items

The role of somatostatin analogues in the treatment of neuroendocrine tumours.
by: Grozinsky-Glasberg, S, et al.
Published: (2008)

Imaging neuroendocrine tumours with radiolabelled somatostatin analogues and X-ray computed tomography: a comparative study.
by: King, C, et al.
Published: (1993)

Radiolabeled Somatostatin Analogues for Diagnosis and Treatment of Neuroendocrine Tumors
by: Valentina Ambrosini, et al.
Published: (2022-02-01)

Localization of neuroendocrine tumours and insulinomas using radiolabelled somatostatin analogues, 123I-Tyr3-octreotide and 111In-pentatreotide.
by: Ur, E, et al.
Published: (1993)

The value of radiolabelled MIBG and octreotide in the diagnosis and management of neuroendocrine tumours.
by: Kaltsas, G, et al.
Published: (2001)

Somatostatin analogues in the control of neuroendocrine tumours: efficacy and mechanisms.
by: Grozinsky-Glasberg, S, et al.
Published: (2008)

Recent advances in radiological and radionuclide imaging and therapy of neuroendocrine tumours.
by: Kaltsas, G, et al.
Published: (2004)

Radionuclide treatment of neuroendocrine tumours with the novel radiolabelled analogue Y-90-SMT 487
by: Carroll, P, et al.
Published: (2003)

Diagnostic Value of Radiolabelled Somatostatin Analogues for Neuroendocrine Tumour Diagnosis: The Benefits and Drawbacks of [<sup>64</sup>Cu]Cu-DOTA-TOC
by: Nasim Vahidfar, et al.
Published: (2022-04-01)

The clinical presentation (symptoms and signs) of sporadic and familial chromaffin cell tumours (phaeochromocytomas and paragangliomas).
by: Kaltsas, G, et al.
Published: (2004)

The somatostatin analogue octreotide inhibits growth of small intestine neuroendocrine tumour cells.
by: Su-Chen Li, et al.
Published: (2012-01-01)

Somatostatin analogues therapy in gastroenteropancreatic neuroendocrine tumours: current aspects and new perspectives
by: Roberto eBaldelli
Published: (2014-02-01)

Comparison of somatostatin receptor expression in patients with neuroendocrine tumours with and without somatostatin analogue treatment imaged with [18F]SiTATE
by: Ralf S. Eschbach, et al.
Published: (2023-01-01)

Transcriptome of GH-producing pituitary neuroendocrine tumours and models are significantly affected by somatostatin analogues
by: Rihards Saksis, et al.
Published: (2023-02-01)

Role of Somatostatin Signalling in Neuroendocrine Tumours
by: Olesja Rogoza, et al.
Published: (2022-01-01)

Treatment of advanced neuroendocrine tumours using combination chemotherapy with lomustine and 5-fluorouracil.
by: Kaltsas, G, et al.
Published: (2002)

Is there a clinical usefulness for radiolabeled somatostatin analogues beyond the consolidated role in NETs?
by: Vincenzo Cuccurullo, et al.
Published: (2017-10-01)

Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors.
by: Kaltsas, G, et al.
Published: (2001)

Paraneoplastic syndromes secondary to neuroendocrine tumours.
by: Kaltsas, G, et al.
Published: (2010)

Somatostatin receptor biology in neuroendocrine and pituitary tumours: part 2--clinical implications.
by: Cakir, M, et al.
Published: (2010)

Somatostatin receptor biology in neuroendocrine and pituitary tumours: part 1--molecular pathways.
by: Cakir, M, et al.
Published: (2010)

The role of chemotherapy in the nonsurgical management of malignant neuroendocrine tumours.
by: Kaltsas, G, et al.
Published: (2001)

The role of chemotherapy management of malignant in the nonsurgical neuroendocrine tumours
by: Kaltsas, G, et al.
Published: (2001)

Patient reported symptoms, coping and quality of life during somatostatin analogue treatment for metastatic small- intestinal neuroendocrine tumours
by: Halfdan Sorbye, et al.
Published: (2020-06-01)

Patient And Nurse Experience Of Using Somatostatin Analogues To Treat Gastroenteropancreatic Neuroendocrine Tumors: Results Of The Somatostatin Treatment Experience Trial (STREET)
by: Ström T, et al.
Published: (2019-10-01)

Chronic Treatment with Somatostatin Analogues in Recurrent Type 1 Gastric Neuroendocrine Tumors
by: Fernando Sebastian-Valles, et al.
Published: (2023-03-01)

Somatostatin Receptor 2 Expression Profiles and Their Correlation with the Efficacy of Somatostatin Analogues in Gastrointestinal Neuroendocrine Tumors
by: Hirofumi Watanabe, et al.
Published: (2022-02-01)

Casting a Wider NET: Pancreatic Exocrine Insufficiency Induced by Somatostatin Analogues among Patients with Neuroendocrine Tumours?
by: Lewis A. Hall, et al.
Published: (2023-03-01)

Advances in the treatment of gastroenteropancreatic neuroendocrine neoplasms with somatostatin analogs
by: Ming Lu, et al.
Published: (2023-03-01)

Update on neuroendocrine tumours
by: Grossman, AB
Published: (2012)

Distinct mechanisms of hypoglycaemia in patients with somatostatin‐secreting neuroendocrine tumours
by: Peter Wiesli, et al.
Published: (2019-10-01)

Interaction between somatostatin analogues and targeted therapies in neuroendocrine tumor cells.
by: Sebastian Krug, et al.
Published: (2019-01-01)

Somatostatin analogues stimulate p27 expression and inhibit the MAP kinase pathway in pituitary tumours.
by: Hubina, E, et al.
Published: (2006)

Somatostatin Analogue Treatment Increases AIP Protein Expression in Somatotroph Tumours from Patients with Acromegaly and in GH3 Cells in vitro.
by: Chahal, H, et al.
Published: (2011)

Initiation of Somatostatin analogues for neuroendocrine tumor patients: a cost-effectiveness analysis
by: Sheila D. Rustgi, et al.
Published: (2021-05-01)

Overview of Radiolabeled Somatostatin Analogs for Cancer Imaging and Therapy
by: Romain Eychenne, et al.
Published: (2020-09-01)

Correction: Interaction between somatostatin analogues and targeted therapies in neuroendocrine tumor cells.
by: Sebastian Krug, et al.
Published: (2020-01-01)

Pituitary imaging using a labelled somatostatin analogue in acromegaly.
by: Ur, E, et al.
Published: (1992)

Radiolabeled Somatostatin Analogs—A Continuously Evolving Class of Radiopharmaceuticals
by: Melpomeni Fani, et al.
Published: (2022-02-01)

The diagnosis and medical management of advanced neuroendocrine tumors.
by: Kaltsas, G, et al.
Published: (2004)